Literature DB >> 15860571

A farnesoid x receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis.

Stefano Fiorucci1, Giovanni Rizzo, Elisabetta Antonelli, Barbara Renga, Andrea Mencarelli, Luisa Riccardi, Stefano Orlandi, Mark Pruzanski, Antonio Morelli, Roberto Pellicciari.   

Abstract

The farnesoid X receptor (FXR) is expressed by and regulates hepatic stellate cells (HSCs). In the present study, we investigated whether 6-ethyl chenodeoxycholic acid (6-ECDCA or INT-747), a semisynthetic derivative of chenodeoxycholic acid (CDCA), modulates tissue metalloproteinase inhibitor (TIMP)-1 and matrix metalloprotease (MMP)-2 expression/activity in HSCs and in the liver of rats rendered cirrhotic by 4-week administration of CCl(4). Exposure of HSCs to FXR ligands increases small heterodimer partner (SHP) mRNA by 3-fold and reduces basal and thrombin-stimulated expression of alpha1(I)collagen, alpha-smooth muscle actin (alpha-SMA), TIMP-1, and TIMP-2 by approximately 60 to 70%, whereas it increased matrix metalloprotease (MMP)-2 activity by 2-fold. In coimmunoprecipitation, electromobility shift, and transactivation experiments, FXR activation/overexpression caused a SHP-dependent inhibition of JunD binding to its consensus element in the TIMP-1 promoter. Inhibition of TIMP-1 expression by SHP overexpression enhanced the sensitivity of HSCs to proapoptogenic stimuli. Administration of 3 mg/kg 6-ECDCA, but not 15 mg/kg ursodeoxycholic acid, resulted in early (3-5-day) induction of SHP and prevention of early up-regulation of TIMP-1 mRNA induced by CCl(4). In the prevention protocol, 4-week administration of 6-ECDCA reduced alpha1(I)collagen, alpha-SMA, and TIMP-1 mRNA by 60 to 80%, whereas it increased MMP-2 activity by 5-fold. In the resolution protocol, administration of 3 mg/kg 6-ECDCA promoted liver fibrosis resolution and increased the apoptosis of nonparenchyma liver cells. By demonstrating that a FXR-SHP regulatory cascade promotes the development of a quiescent phenotype and increases apoptosis of HSCs, this study establishes that FXR ligands may be beneficial in treatment of liver fibrosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15860571     DOI: 10.1124/jpet.105.084905

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  57 in total

1.  Roles of microRNA-29a in the antifibrotic effect of farnesoid X receptor in hepatic stellate cells.

Authors:  Jiang Li; Yifei Zhang; Ramalinga Kuruba; Xiang Gao; Chandrashekhar R Gandhi; Wen Xie; Song Li
Journal:  Mol Pharmacol       Date:  2011-04-21       Impact factor: 4.436

Review 2.  New perspectives for the treatment of cholestasis: lessons from basic science applied clinically.

Authors:  James L Boyer
Journal:  J Hepatol       Date:  2006-12-18       Impact factor: 25.083

Review 3.  Role of nuclear receptor SHP in metabolism and cancer.

Authors:  Yuxia Zhang; Curt H Hagedorn; Li Wang
Journal:  Biochim Biophys Acta       Date:  2010-10-20

Review 4.  The interaction between HCV and nuclear receptor-mediated pathways.

Authors:  Zoe Raglow; Carly Thoma-Perry; Richard Gilroy; Yu-Jui Yvonne Wan
Journal:  Pharmacol Ther       Date:  2011-05-18       Impact factor: 12.310

5.  Filtrate of fermented mycelia from Antrodia camphorata reduces liver fibrosis induced by carbon tetrachloride in rats.

Authors:  Wen-Chuan Lin; Shu-Ching Kuo; Wei-Lii Lin; Hsun-Lang Fang; Bor-Chen Wang
Journal:  World J Gastroenterol       Date:  2006-04-21       Impact factor: 5.742

6.  Loss of FXR protects against diet-induced obesity and accelerates liver carcinogenesis in ob/ob mice.

Authors:  Yanqiao Zhang; Xuemei Ge; Lydia A Heemstra; Wei-Dong Chen; Jiesi Xu; Joseph L Smith; Huiyan Ma; Neda Kasim; Peter A Edwards; Colleen M Novak
Journal:  Mol Endocrinol       Date:  2012-01-19

Review 7.  Extracellular matrix and liver disease.

Authors:  Elena Arriazu; Marina Ruiz de Galarreta; Francisco Javier Cubero; Marta Varela-Rey; María Pilar Pérez de Obanos; Tung Ming Leung; Aritz Lopategi; Aitor Benedicto; Ioana Abraham-Enachescu; Natalia Nieto
Journal:  Antioxid Redox Signal       Date:  2014-01-08       Impact factor: 8.401

8.  Farnesoid X receptor-Acting through bile acids to treat metabolic disorders.

Authors:  Yanqiao Zhang
Journal:  Drugs Future       Date:  2010-08-01       Impact factor: 0.148

9.  Farnesoid X Receptor Protects against Kidney Injury in Uninephrectomized Obese Mice.

Authors:  Zhibo Gai; Ting Gui; Christian Hiller; Gerd A Kullak-Ublick
Journal:  J Biol Chem       Date:  2015-12-11       Impact factor: 5.157

10.  Inhibition of endothelin-1-mediated contraction of hepatic stellate cells by FXR ligand.

Authors:  Jiang Li; Ramalinga Kuruba; Annette Wilson; Xiang Gao; Yifei Zhang; Song Li
Journal:  PLoS One       Date:  2010-11-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.